Gilead Sciences Unveils Positive Data on HIV Prevention Shot

Thursday, 12 September 2024, 05:44

Gilead Sciences' HIV prevention shot lenacapavir shows a remarkable 96% reduction in infections, according to new trial results. This breakthrough highlights the potential of lenacapavir in HIV prevention for various populations. More than 3,200 participants, including cisgender men, transgender women, and gender nonbinary individuals, were involved in this significant study.
LivaRava_Medicine_Default.png
Gilead Sciences Unveils Positive Data on HIV Prevention Shot

Overview of Gilead's HIV Prevention Shot

Gilead Sciences has recently revealed positive findings regarding its HIV prevention shot, lenacapavir. In a substantial clinical trial involving over 3,200 participants, including cisgender men, transgender women, and gender nonbinary individuals, lenacapavir has demonstrated a 96% reduction in HIV infections.

Significance of the Results

This remarkable outcome signifies a promising step forward in HIV prevention. With lenacapavir being administered twice a year, this innovative shot offers an effective option for those at high risk of HIV infection.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe